Reviews/Targeted Therapy Prostate Cancer/Rucaparib benefit in non-BRCA homologous recombination repair metastatic castration-resistant prostate cancer
PARP · PC-PARP-03 · v2
The claim says rucaparib works well in prostate cancer patients whose tumours carry DNA-repair faults other than BRCA, and it specifically names two such faults: CDK12 and ATM. The one trial in this corpus that actually tested rucaparib in exactly these patients [2] found almost no response in those two groups: none of the evaluable CDK12 patients responded on imaging, and only a small fraction of ATM patients did, with no responses at all in the deepest ATM subgroups. A separate CDK12 cohort [16] likewise saw no response to PARP inhibitors. The trial did show responses in some other non-BRCA genes, but not in the two the claim chose to highlight. Because the direct evidence points the opposite way for the named genes, the panel rejected the claim as worded.
The only rucaparib-specific, on-population trial here [2] enrolled 78 non-BRCA patients and reported radiographic responses in ATM of 2/19 (10.5%) and in CDK12 of 0/10 (0%), with no radiographic or PSA responses among 11 patients with biallelic ATM loss or 11 with ATM germline mutations. The same trial [2] did observe responses in alterations of PALB2, FANCA, BRIP1 and RAD51B. A retrospective CDK12-altered cohort [16] reported that of 11 men given a PARP inhibitor (olaparib n=10, rucaparib n=1), none had a PSA response. Rucaparib's activity in BRCA is documented separately [1] (ORR 43.5%, PSA response 54.8%, N=115), but that is the population the claim explicitly moves beyond. The contested point: The evidence splits on which non-BRCA genes carry the signal: [2] shows genuine responses in PALB2 and similar genes, yet none in the CDK12 and ATM subgroups the claim names. The division is therefore not whether rucaparib works beyond BRCA at all, but whether it works in the specific exemplars chosen.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim names CDK12 and ATM as the beyond-BRCA wins, yet [2] reports exactly these as non-responders: CDK12 0/10 (0%) radiographic response and no responses at all in biallelic or germline ATM. The claim asserts the inverse of its only direct evidence.
Olaparib trials [4][5][6] and the MAGNITUDE niraparib data are a different drug/agent and cannot substantiate a rucaparib-specific activity claim; using them would be an indirectness/drug-mismatch overreach.
Where it remains uncertain. [2] supports a broader non-BRCA signal yet contradicts the two named genes; [16] adds a PARP-inhibitor null in CDK12 but rests almost entirely on olaparib (10 of 11 patients).
Aleatory
The CDK12 and ATM response rates in [2] rest on few evaluable patients (CDK12 0/10, ATM 2/19), so the point estimates carry wide sampling variability.
Epistemic
Direct rucaparib evidence in CDK12 reduces to [2]'s small subgroup, since [16]'s 11 PARP-inhibitor patients were 10 olaparib and 1 rucaparib.
Inferential
Olaparib results [4][5][6] and niraparib [10] cannot be inferred onto rucaparib; doing so would be a drug-mismatch overreach.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Establishes rucaparib activity is confined to the BRCA population the claim explicitly moves 'beyond'; no support for CDK12/ATM.
“Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.”
Panel auditInternal validity: medium · scope of inference: Rucaparib antitumour activity in mCRPC patients with deleterious BRCA1/2 alterations after AR-directed and taxane therapy.Key limitations: single-arm, no comparator · BRCA-only population · does not address non-BRCA HRR genes
Independent cohort confirming a PARP-inhibitor null in CDK12-altered mCRPC (predominantly olaparib).
“Eleven men received a PARP inhibitor (olaparib [n = 10], rucaparib [n = 1]), and none had a PSA response (median PFS, 3.6 months).”
Panel auditInternal validity: low · scope of inference: Clinical course and therapy outcomes, including PARP inhibitors, in CDK12-altered prostate cancer.Key limitations: retrospective · only 1 rucaparib patient · tiny PARP-treated subgroup
Directly refutes the clinically-meaningful-activity claim for the two genes named (CDK12, ATM).
“In this prospective, genomics-driven study of rucaparib in mCRPC, we found limited radiographic/PSA responses to PARP inhibition in men with alterations in ATM, CDK12 , or CHEK2 . However, patients with alterations in other DDR-associated genes (e.g., PALB2 ) may benefit from PARP inhibition.”
Panel auditInternal validity: medium · scope of inference: Rucaparib response in mCRPC patients with deleterious non-BRCA DDR alterations, especially ATM, CDK12 and CHEK2.Key limitations: very small per-gene subgroups · single-arm, no control · descriptive only, no significance testing
The drug studied is olaparib; the abstract reports no rucaparib data, so it cannot report on the rucaparib claim.
Panel auditInternal validity: high · scope of inference: Olaparib efficacy in mCRPC with HRR gene alterations after a next-generation hormonal agent.Key limitations: wrong drug (olaparib, not rucaparib) · cohort A pools BRCA1/BRCA2/ATM
4 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct primary evidence contradicts the claim's named CDK12 and ATM subgroups, so the claim as worded is refuted despite a valid broader signal in other HRR genes.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Dedicated rucaparib CDK12 and ATM cohort. Current rucaparib evidence in the named genes is limited to [2]'s small subgroups and [16]'s single rucaparib patient. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective rucaparib trial powered specifically for CDK12 and ATM mCRPC subgroups with pre-specified response endpoints.
Open question: Does rucaparib produce any meaningful response in CDK12-altered mCRPC when tested in a dedicated cohort rather than the small subgroup of [2]? Why it is still open: [2] reported 0/10 radiographic response in CDK12 and [16]'s null included only one rucaparib patient, so rucaparib-specific CDK12 evidence is very thin.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19